Mustang Bio, Inc. (MBIO) Stock Price, News, Quote & History - Yahoo Finance

By Yahoo! Finance | Jun 17, 2024 at 01:32 PM EST

Mustang Bio reports positive results from Phase 1/2 trial of MB-106 CAR-T therapy for Waldenstrom Macroglobulinemia. 90% response rate with durable responses, including one patient in remission at 31 months. Outpatient administration feasible.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.